Your activity: 8 p.v.

Dulaglutide: Drug information

Dulaglutide: Drug information
(For additional information see "Dulaglutide: Patient drug information" and see "Dulaglutide: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Risk of thyroid C-cell tumors:

In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.

Dulaglutide is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of dulaglutide and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with dulaglutide.

Brand Names: US
  • Trulicity
Brand Names: Canada
  • Trulicity
Pharmacologic Category
  • Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Dosing: Adult

Note: Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (Ref). May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (Ref).

Diabetes mellitus, type 2, treatment

Diabetes mellitus, type 2, treatment:

Note: May be used as an adjunctive agent or alternative monotherapy for select patients, including those in whom initial therapy with lifestyle intervention and metformin failed, or who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease, when weight loss is desired, and/or in patients with an HbA1c relatively far from goal (eg, HbA1c 9% to 10%) and type 1 diabetes is not likely (Ref).

SUBQ: Initial: 0.75 mg once weekly; may increase to 1.5 mg once weekly after 4 to 8 weeks if needed to achieve glycemic goals (Ref). If additional glycemic control is needed, may further increase to 3 mg once weekly after at least 4 weeks on the 1.5 mg weekly dose and then to a maximum of 4.5 mg once weekly after at least 4 weeks on the 3 mg weekly dose.

Missed doses: Missed dose should be administered as soon as possible within 3 days; resume usual schedule thereafter. If there are <3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (Ref). Use caution when initiating or escalating doses; new onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzable (Ref): No supplemental dose or dosage adjustment necessary; use with caution due to limited clinical evidence (Ref).

Peritoneal dialysis: Unlikely to be dialyzable (Ref): No dosage adjustment necessary; use with caution due to limited clinical evidence (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Pediatric

(For additional information see "Dulaglutide: Pediatric drug information")

Diabetes mellitus, type 2; adjunct

Diabetes mellitus (DM), type 2; adjunct:

Note: Glucagon-like peptide-1 (GLP-1) receptor agonists may be considered an additional therapeutic option in pediatric patients with type 2 DM who are ≥3 months post-diagnosis with an HbA1c of ≥6.5% while on metformin therapy (maximized) in addition to a healthy lifestyle (eg, diet and exercise) with or without insulin (Ref).

Children ≥10 years and Adolescents <18 years: SUBQ: Initial: 0.75 mg once weekly; if additional glycemic control needed after 4 weeks, may increase to 1.5 mg once weekly (Ref).

Adolescents ≥18 years: SUBQ: Initial: 0.75 mg once weekly; if additional glycemic control needed after 4 weeks, may increase to 1.5 mg once weekly. If additional glycemic control is needed, may titrate in 1.5 mg increments after at least 4 weeks at current dose up to a maximum weekly dose: 4.5 mg/dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children ≥10 years and Adolescents: SUBQ:

Mild to severe impairment: No dosage adjustment necessary. Use caution when initiating or escalating doses; new-onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Pen-injector, Subcutaneous [preservative free]:

Trulicity: 0.75 mg/0.5 mL (0.5 mL); 1.5 mg/0.5 mL (0.5 mL); 3 mg/0.5 mL (0.5 mL); 4.5 mg/0.5 mL (0.5 mL) [contains polysorbate 80]

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Pen-injector, Subcutaneous:

Trulicity: 0.75 mg/0.5 mL (0.5 mL); 1.5 mg/0.5 mL (0.5 mL) [contains polysorbate 80]

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf#page=27, must be dispensed with this medication.

Administration: Adult

SUBQ: Do not inject intravenously or intramuscularly. Inject subcutaneously into the upper arm, thigh, or abdomen; when administering within the same body region, use a different injection site each week. Administer once weekly on the same day each week, without regard to meals or time of day. The day of weekly administration may be changed, as long as the last dose was administered ≥3 days before. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another. Dulaglutide is a single-dose device that does not require priming before injection (Ref).

Administration: Pediatric

SUBQ: Dulaglutide is available as a single-dose device that does not require priming prior to use. Inject SUBQ into the upper arm, thigh, or abdomen; when administering within the same body region, use a different injection site. Administer once weekly on the same day each week, without regard to meals or time of day. The day of weekly administration may be changed if the last dose was administered ≥3 days before. Do not inject IV or IM. If using concomitantly with insulin, administer as separate injections (do not mix); may inject in the same body region as insulin, but not adjacent to one another.

Missed doses: Missed dose should be administered as soon as possible within 3 days; resume usual schedule thereafter. If there are <3 days until next scheduled dose, omit the missed dose and resume administration at the next scheduled weekly dose.

Use: Labeled Indications

Diabetes mellitus, type 2, treatment: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus; risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Medication Safety Issues
Sound-alike/look-alike issues:

Trulicity may be confused with Tanzeum [DSC], Toujeo, Tradjenta, Tresiba

Adverse Reactions (Significant): Considerations
Acute kidney injury

Acute kidney injury (AKI), which sometimes requires dialysis, has been reported with dulaglutide and other glucagon-like peptide 1 receptor agonists. According to the manufacturer, AKI secondary to dulaglutide was seen mostly in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In a post-hoc analysis of multiple clinical trials, dulaglutide was not associated with an increase in adverse effects reflecting potential acute kidney failure (Ref).

Mechanism: Non–dose-related; exact mechanism is unknown. Pre-renal AKI may occur due to dehydration and volume contraction secondary to gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) (Ref).

Onset: Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on GI symptoms, initiation or dosage adjustment of concomitant medications, and/or comorbid conditions (Ref).

Risk factors:

• Volume contraction (eg, during periods of severe vomiting or diarrhea) (Ref)

• Co-administration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (Ref)

• Preexisting kidney impairment

Diabetic retinopathy

An increased incidence of diabetic retinopathy (DR) was noted during the REWIND study, a clinical trial evaluating the impact of dulaglutide on cardiovascular outcomes in patients with type 2 diabetes (Ref); the proportion of patients with DR complications was larger among patients with a prior history of DR. In addition, rapid reductions in HbA1c are associated with an early worsening of DR (Ref); in an analysis of DR complications due to another glucagon-like peptide 1 (GLP-1) receptor agonist (semaglutide), the increased risk of DR was mainly observed in patients with preexisting DR and primarily attributable to the magnitude and rapidity of reduction in HbA1c (Ref). Clinicians should note that this effect has been observed with SUBQ dulaglutide, exenatide, and semaglutide but not other GLP-1 receptor agonists (Ref).

Mechanism: Unknown; in general, worsening of preexisting DR is a known consequence of rapid improvement of hyperglycemia, especially in patients with uncontrolled diabetes (Ref). Although unlikely, a direct toxic effect or potential angiogenic action of dulaglutide has not been ruled out (Ref).

Onset: Varied; clinicians should note that DR is a progressive condition and the onset of DR complications may vary.

Risk factors:

• Preexisting diabetic retinopathy

• In general, the risk of early worsening of DR is increased when intensive treatment is initiated in patients with long-standing poor glycemic control (Ref)

Gallbladder disease

Gallbladder disease and biliary tract disease, including cholelithiasis, acute cholecystitis, and cholestasis, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including dulaglutide (Ref); some have required hospitalization or cholecystectomy (Ref). Resolution of biliary stones following discontinuation has been documented with other GLP-1 receptor agonists (eg, liraglutide) (Ref); one patient with dulaglutide-associated cholecystitis successfully continued dulaglutide therapy post-cholecystectomy without recurrent complications (Ref).

Mechanism: Dose- and time-related (Ref); not fully understood. Animal studies and in vitro data have demonstrated that GLP-1 enhances the proliferation and functional activity of cholangiocytes, which may result in gallbladder diseases (Ref). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (Ref).

Onset: Varied. An increased risk was seen following >26 weeks of therapy (Ref); one case report, acute cholecystitis developed after 16 months of treatment with dulaglutide (Ref).

Risk factors:

• Higher doses (Ref)

• Longer duration of treatment (eg, >26 weeks (Ref))

• Substantial or rapid weight loss has been associated with an increased risk with other GLP-1 receptor agonists used for weight loss (eg, liraglutide, semaglutide) (Ref)

GI symptoms

GI effects, mainly diarrhea, nausea, and vomiting, are the most common adverse reactions associated with glucagon-like peptide 1 (GLP-1) receptor agonists, including dulaglutide (Ref). Symptoms may sometimes be severe. Abdominal pain, decreased appetite, and dyspepsia may also occur. GI effects tend to occur during dose escalation and decrease over time (Ref); may result in treatment discontinuation.

In general, long-acting GLP-1 receptor agonists (eg, dulaglutide, once-weekly exenatide, liraglutide, semaglutide) are associated with less nausea and vomiting but more diarrhea when compared to their short-acting counterparts (Ref). Dulaglutide may be associated with a lower risk of diarrhea when compared to liraglutide (Ref). In the SUSTAIN-7 trial comparing once-weekly semaglutide to once-weekly dulaglutide, rates of gastrointestinal effects were similar for both doses of semaglutide (0.5 mg and 1 mg) and high-dose dulaglutide (1.5 mg) (Ref).

Mechanism: Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation of centers involved in appetite regulation, satiety, and nausea (Ref).

Onset: Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) and during dose escalation (Ref). In a post-hoc analysis of 2 clinical trials, GI effects were most common during the first 2 weeks of treatment and the incidence declined rapidly thereafter (Ref).

Risk factors:

• Dose; generally greater with higher doses

• In general, rapid titration of GLP-1 receptor agonists is associated with a higher risk of GI symptoms

Hypersensitivity reactions

Serious, immediate hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with glucagon-like peptide 1 (GLP-1) receptor agonists (Ref). Exendin-based GLP-1 receptor agonists (eg, exenatide, lixisenatide) are associated with a doubling of reporting odds of anaphylactic reaction compared with human-analogue GLP-1 receptor agonists (eg, liraglutide, dulaglutide, albiglutide, semaglutide) (Ref).

Delayed hypersensitivity reactions such as a morbilliform rash (Ref) and injection site reactions (Ref) have been documented.

Mechanism: Non–dose-related; immunologic.

Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (Ref).

Delayed hypersensitivity reactions: T-cell mediated (Ref).

Note: The risk of immune-mediated adverse effects is low with dulaglutide, despite the formation of neutralizing antibodies (Ref).

Onset:

Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (Ref).

Delayed hypersensitivity reactions: Variable; typically maculopapular (morbilliform, exanthematous) eruptions occur 4 to 14 days after drug initiation (Ref), although has been reported up to 5 weeks after starting dulaglutide (Ref).

Risk factors:

• Cross-reactivity between GLP-1 receptor agonists is unknown (Ref). Until further studies are available, dulaglutide should be used with caution in patients with a history of anaphylaxis or angioedema to other GLP-1 receptor agonists. Skin tests have been used in patients with histories of immediate hypersensitivity reactions to GLP-1 receptor agonists (Ref).

Medullary thyroid carcinoma

In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with dulaglutide. It is unknown whether dulaglutide causes thyroid C-cell tumors in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined. According to the manufacturer, one human cases of medullary thyroid carcinoma (MTC) was reported with dulaglutide during clinical trials in a patient with pretreatment calcitonin levels ~8 times the upper limit of normal. In addition, a single case of C-cell hyperplasia with elevated calcitonin levels was noted during the REWIND trial (Ref).

Mechanism: Unknown. Animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of glucagon-like peptide 1 (GLP-1) receptor agonists may be rodent-specific. Humans have far fewer C-cells than rodents, and expression of the GLP-1 receptor in human C-cells is very low (Ref).

Risk factors:

• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) may be at an increased risk

Pancreatitis

Cases of acute pancreatitis (including hemorrhagic pancreatitis and necrotizing pancreatitis with some fatalities), chronic pancreatitis, and pancreatic adenocarcinoma have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists) (Ref). Acute pancreatitis was observed with dulaglutide at rates similar to placebo during the AWARD trial program and the REWIND trial (Ref).

Mechanism: Causality has not been firmly established (Ref). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (Ref).

Onset: Not well characterized.

Risk factors:

• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis

• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (Ref).

• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%:

Endocrine & metabolic: Hypoglycemia (≤77%; highest incidence seen with adjunctive use of insulin or sulfonylureas; severe hypoglycemia: ≤3%; highest incidence seen with adjunctive use of prandial insulin)

Gastrointestinal: Diarrhea (9% to 13%) (table 1), nausea (12% to 21%) (table 2), vomiting (6% to 13%) (table 3)

Dulaglutide: Adverse Reaction: Diarrhea

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

13%

7%

1.5 mg once weekly

834

568

9%

7%

0.75 mg once weekly

836

568

Dulaglutide: Adverse Reaction: Nausea

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

21%

5%

1.5 mg once weekly

834

568

12%

5%

0.75 mg once weekly

836

568

Dulaglutide: Adverse Reaction: Vomiting

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

13%

2%

1.5 mg once weekly

834

568

6%

2%

0.75 mg once weekly

836

568

1% to 10%:

Cardiovascular: First-degree atrioventricular block (2%), prolongation P-R interval on ECG (3%), sinus tachycardia (6%), sustained tachycardia (2%)

Endocrine & metabolic: Diabetic retinopathy (2%; more common in patients with history of diabetic retinopathy at baseline) (table 4)

Dulaglutide: Adverse Reaction: Diabetic Retinopathy

Drug (Dulaglutide)

Placebo

Dose

Indication

Comments

1.9%

1.5%

1.5 mg once weekly

Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors

N/A

9%

6%

1.5 mg once weekly

Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors

Patients with a history of diabetic retinopathy at baseline

1%

1%

1.5 mg once weekly

Type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors

Patients without a known history of diabetic retinopathy

Gastrointestinal: Abdominal distension (2% to 3%), abdominal pain (7% to 9%) (table 5), constipation (4%), decreased appetite (5% to 9%) (table 6), dyspepsia (4% to 6%) (table 7), eructation (2%), flatulence (3%), gastroesophageal reflux disease (2%)

Dulaglutide: Adverse Reaction: Abdominal Pain

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

9%

5%

1.5 mg once weekly

834

568

7%

5%

0.75 mg once weekly

836

568

Dulaglutide: Adverse Reaction: Decreased Appetite

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

9%

2%

1.5 mg once weekly

834

568

5%

2%

0.75 mg once weekly

836

568

Dulaglutide: Adverse Reaction: Dyspepsia

Drug (Dulaglutide)

Placebo

Dose

Number of Patients (Dulaglutide)

Number of Patients (Placebo)

6%

2%

1.5 mg once weekly

834

568

4%

2%

0.75 mg once weekly

836

568

Immunologic: Antibody development (2%; neutralizing: <1%)

Nervous system: Fatigue (4% to 6%)

<1%:

Gastrointestinal: Pancreatitis

Hypersensitivity: Hypersensitivity reaction

Local: Injection-site reaction

Frequency not defined: Gastrointestinal: Increased serum amylase, increased serum lipase

Postmarketing:

Dermatologic: Morbilliform rash (Rzepka 2020)

Gastrointestinal: Acute pancreatitis (Gerstein 2019), biliary tract disease (He 2022), cholecystitis (Butler 2021) (table 8), cholelithiasis (Gerstein 2019; Pratley 2018), cholestasis (He 2022), gallbladder disease (He 2022)

Dulaglutide: Adverse Reaction: Cholecystitis

Drug (Dulaglutide)

Placebo

Comments

0.5%

0.3%

Serious events of acute cholecystitis

Hepatic: Hepatitis, increased liver enzymes

Hypersensitivity: Anaphylaxis (Milicevic 2016), angioedema (Milicevic 2016)

Renal: Acute kidney injury (Tuttle 2017)

Contraindications

Serious hypersensitivity to dulaglutide or any component of the formulation; personal or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)

Canadian labeling: Additional contraindications (not in US labeling): Pregnancy; breast-feeding

Warnings/Precautions

Disease-related concerns:

• Bariatric surgery:

- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).

- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.

• GI disease: Use is not recommended in patients with preexisting severe GI disease, including severe gastroparesis.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Renal impairment: Use with caution in patients with renal impairment.

Other warnings/precautions:

• Appropriate use: Diabetes mellitus: Not recommended for first-line therapy in patients inadequately controlled on diet and exercise alone. Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy

Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Risk D: Consider therapy modification

Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. Risk X: Avoid combination

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides. Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin. Risk D: Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Semaglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. Risk X: Avoid combination

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Reproductive Considerations

Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2021; Alexopoulos 2019; Egan 2020)

Pregnancy Considerations

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2021; Blumer 2013).

Agents other than dulaglutide are currently recommended to treat diabetes mellitus in pregnancy (ADA 2021).

Breastfeeding Considerations

It is not known if dulaglutide is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother

Dietary Considerations

Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Monitoring Parameters

Plasma glucose; renal function (in patients reporting severe GI reactions); signs/symptoms of pancreatitis; worsening diabetic retinopathy (in patients with a prior history).

HbA1c: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. Note: In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA1c is discordant with serum glucose levels or symptoms, consider evaluating HbA1c in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).

Reference Range

Recommendations for glycemic control in patients with diabetes:

Nonpregnant adults (ADA 2021):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics). Note: In patients using a continuous glucose monitoring system, a goal of time in range >70% with time below range <4% is recommended and is similar to a goal HbA1c <7%.

Preprandial capillary blood glucose: 80 to 130 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): <180 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Older adults (≥65 years of age) (ADA 2021):

Note: May consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).

HbA1c: <7% to 7.5% (healthy); <8% to 8.5% (complex/intermediate health). Note: Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA1c level.

Preprandial capillary blood glucose: 80 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health).

Bedtime capillary blood glucose: 80 to 180 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health).

Classification of hypoglycemia (ADA 2021):

Level 1: 54 to 70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.

Level 2: <54 mg/dL; threshold for neuroglycopenic symptoms; requires immediate action.

Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.

Mechanism of Action

Dulaglutide is an agonist of human glucagon-like peptide-1 (GLP-1) receptor and augments glucose dependent insulin secretion and slows gastric emptying.

Pharmacokinetics

Bioavailability: 47% to 65%.

Distribution: Central volume, mean: 3.09 L; peripheral volume, mean: 5.98 L.

Metabolism: Degradation to amino acids by protein catabolism pathways.

Half-life elimination: ~5 days.

Time to peak, plasma: 24 to 72 hours.

Pharmacokinetics: Additional Considerations

Altered kidney function: Dulaglutide systemic exposure increased by 20%, 28%, 14%, and 12% for mild, moderate, and severe renal impairment, and ESRD, respectively.

Hepatic function impairment: Dulaglutide systemic exposure decreased by 23%, 33%, and 21% for mild, moderate, and severe hepatic impairment, respectively.

Pricing: US

Solution Pen-injector (Trulicity Subcutaneous)

0.75 mg/0.5 mL (per 0.5 mL): $265.97

1.5 mg/0.5 mL (per 0.5 mL): $265.97

3 mg/0.5 mL (per 0.5 mL): $265.97

4.5 mg/0.5 mL (per 0.5 mL): $265.97

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Trulicity (AE, AT, BB, BE, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, JP, KR, LB, LT, LU, MT, MY, NL, NO, PL, PT, RO, SE, SG, SI, SK, TH, TW)


For country code abbreviations (show table)
  1. Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. JAMA. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981 [PubMed 31087027]
  2. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271-284. doi:10.1016/j.diabres.2012.09.008 [PubMed 23010561]
  3. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960. [PubMed 30461693]
  4. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. [PubMed 29370047]
  5. American Diabetes Association (ADA). Standards of medical care in diabetes–2019. Diabetes Care. 2019;42(suppl 1):S1-S2. https://diabetesjournals.org/care/issue/42/Supplement_1. Accessed December 2, 2022.
  6. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. Diabetes Care. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.
  7. Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387(5):433-443. doi:10.1056/NEJMoa2204601 [PubMed 35658022]
  8. Based on expert opinion.
  9. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336-347. doi:10.1111/dom.12824 [PubMed 27860132]
  10. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation [published correction appears in Endocrinology. 2012;153(2):1000. Moerch, Ulrik [added]]. Endocrinology. 2010;151(4):1473-1486. doi:10.1210/en.2009-1272 [PubMed 20203154]
  11. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  12. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249. [PubMed 24194617]
  13. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  14. Butler J, Bjurstrom M, Marceau A. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy [published online ahead of print, 2021 Feb 17]. Am J Health Syst Pharm. 2021;zxab045. doi:10.1093/ajhp/zxab045 [PubMed 33594405]
  15. Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. J Investig Allergol Clin Immunol. 2020;30(5):367-369. doi:10.18176/jiaci.0521 [PubMed 32301438]
  16. Dauner DG, Farley JF. Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy [published online ahead of print, 2021 Feb 8]. Expert Opin Drug Saf. 2021;10.1080/14740338.2021.1887136. doi:10.1080/14740338.2021.1887136 [PubMed 33554677]
  17. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033 [PubMed 30291106]
  18. Dungan K, DeSantis A. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 23, 2021.
  19. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial [published correction appears in Arch Ophthalmol. 1998;116(11):1469]. Arch Ophthalmol. 1998;116(7):874-886. doi:10.1001/archopht.116.7.874 [PubMed 9682700]
  20. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment [published correction appears in N Engl J Med. 2014;370(23):2253]. N Engl J Med. 2014;370(9):794-797. doi:10.1056/NEJMp1314078 [PubMed 24571751]
  21. Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019 [PubMed 32736942]
  22. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156. doi:10.1053/j.gastro.2011.02.018 [PubMed 21334333]
  23. Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474-1481. doi:10.1001/jamainternmed.2016.1531 [PubMed 27478902]
  24. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3-4):202-230. doi:10.1900/RDS.2014.11.202 [PubMed 26177483]
  25. Food and Drug Administration. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Published March 14, 2013. Accessed March 26, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre
  26. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139. doi:10.4158/CS-2019-0472 [PubMed 32022600]
  27. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3 [PubMed 31189511]
  28. Gether IM, Nexøe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019;104(7):2463-2472. doi:10.1210/jc.2018-01008 [PubMed 30137354]
  29. Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16(11):1041-1047. doi:10.1111/dom.12297 [PubMed 24702687]
  30. Guo L, Zhang B, Hou J, Zhou Z. Evaluation of characteristics of gastrointestinal adverse events with once-weekly dulaglutide treatment in Chinese patients with type 2 diabetes: a post hoc pooled analysis of two randomized trials. Diabetes Ther. 2020;11(8):1821-1833. doi:10.1007/s13300-020-00869-z [PubMed 32621083]
  31. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;e220338. doi:10.1001/jamainternmed.2022.0338 [PubMed 35344001]
  32. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524-536. doi:10.1111/dom.12849 [PubMed 27981757]
  33. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019 [PubMed 32998798]
  34. Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017;19(3):401-411. doi:10.1111/dom.12833 [PubMed 27883260]
  35. Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. Aging Clin Exp Res. 2015;27(5):751-753. doi:10.1007/s40520-015-0335-2 [PubMed 25725635]
  36. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond). 2009;33(7):786-795. doi: 10.1038/ijo.2009.79. [PubMed 19417773]
  37. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin EndocrinolMetab. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198 [PubMed 30903688]
  38. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141 [PubMed 27633186]
  39. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827 [PubMed 27295427]
  40. Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58(7):990-997. doi:10.1136/gut.2008.150870 [PubMed 18829977]
  41. Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133(1):244-255. doi:10.1053/j.gastro.2007.04.007 [PubMed 17631146]
  42. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  43. Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obes Metab. 2016;18(5):533-536. doi:10.1111/dom.12640 [PubMed 26847401]
  44. Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647-654. doi:10.2337/dc16-0984 [PubMed 28283565]
  45. Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42(10):1912-1920. doi:10.2337/dc19-0415 [PubMed 31399438]
  46. Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira Barbosa M. Anaphylaxis to long-acting release exenatide. J Investig Allergol Clin Immunol. 2018;28(5):332-334. doi:10.18176/jiaci.0274 [PubMed 30350785]
  47. Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. A case report of allergy to exenatide. J Allergy Clin Immunol Pract. 2014;2(6):822-823. doi:10.1016/j.jaip.2014.05.011 [PubMed 25439386]
  48. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3. [PubMed 22354457]
  49. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 [PubMed 26132939]
  50. Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes Endocrinol. 2020;8(1):13-14. doi:10.1016/S2213-8587(19)30382-1 [PubMed 31806579]
  51. Pratley RE, Aroda VR, Catarig AM, et al. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open. 2020;10(11):e037883. Published 2020 Nov 16. doi:10.1136/bmjopen-2020-037883 [PubMed 33199417]
  52. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. doi:10.1016/S2213-8587(18)30024-X [PubMed 29397376]
  53. Refer to manufacturer’s labeling.
  54. Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10(1):5-19. doi:10.1007/s13300-018-0535-9 [PubMed 30506340]
  55. Rzepka PV, Kaffenberger JA. A case of morbilliform drug eruption to dulaglutide. J Clin Aesthet Dermatol. 2020;13(4):13. [PubMed 33144906]
  56. Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022;23(7):872-902. doi:10.1111/pedi.13409 [PubMed 36161685]
  57. Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. Diabetes Care. 2019;42(9):e141-e142. doi:10.2337/dc19-0720 [PubMed 31296642]
  58. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(10):CD006423. doi:10.1002/14651858.CD006423.pub2 [PubMed 21975753]
  59. Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes. 2017;66(6):1453-1460. doi:10.2337/db16-1364 [PubMed 28533296]
  60. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720 [PubMed 23440284]
  61. Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. Journal of Pharmacy Technology. 2014;30(5):182-186. doi:10.1177/8755122514539462
  62. Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015;17(1):35-42. doi:10.1089/dia.2014.0188 [PubMed 25375397]
  63. Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care. 2015;38(6):1089-1098. doi:10.2337/dc13-2983 [PubMed 25633664]
  64. Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2022.
  65. Trulicity (dulaglutide) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; August 2022.
  66. Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab. 2017;19(3):436-441. doi:10.1111/dom.12816 [PubMed 27766728]
  67. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168‐2176. doi:10.2337/dc13-2759 [PubMed 24842985]
  68. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897. doi:10.1111/dom.13172 [PubMed 29178519]
  69. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849‐858. doi:10.1111/dom.12479 [PubMed 25912221]
  70. Wexler DJ. Initial management of blood glucose in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 14, 2020.
  71. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068 [PubMed 23622135]
Topic 97148 Version 181.0